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Detecting  and characterizing  of  anti-drug  antibodies  (ADA)  against  a protein  therapeutic  are  crucially
important  to  monitor  the  unwanted  immune  response.  Usually  a multi-tiered  approach  that  initially
rapidly  screens  for positive  samples  that  are  subsequently  conﬁrmed  in  a separate  assay  is employed
for  testing  of patient  samples  for  ADA  activity.  In  this  manuscript  we  evaluate  the  ability  of  different
methods  used  to  classify  subject  with  screening  and  competition  based  conﬁrmatory  assays.  We  ﬁnd
that for  the overall  performance  of  the  multi-stage  process  the  method  used  for  conﬁrmation  is most
important  where  a  t-test  is  best  when  differences  are  moderate  to large.  Moreover  we  ﬁnd  that,  whennti-drug antibody
onﬁrmatory
ut point
mmunoassay
mmunogenicity
creening
differences  between  positive  and  negative  samples  are  not  sufﬁciently  large,  using  a competition  based
conﬁrmation  step  does yield  poor  classiﬁcation  of  positive  samples.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).peciﬁcity
. Introduction
Detecting and characterizing of anti-drug antibodies (ADA)
gainst a protein therapeutic are crucially important to monitor
he unwanted immune response. Usually a multi-tiered approach
hat initially rapidly screens for positive samples that are subse-
uently conﬁrmed in a separate assay is employed for testing of
atient samples for ADA presence. Several regulatory guidelines
1–3] and white papers [4–6] describe the testing strategies, assay
ormats, validation requirements and performance expectations for
uch assays have been published.
In order to use either screening or conﬁrmatory assays, estab-
ishing cut points that are used to classify into negative and positive
amples are paramount. An upper negative limit of 95% for the
creening cut point is recommended [1,2,4,6], resulting in a 5%
alse-positive rate. The subsequent conﬁrmation assay used here
ims to eliminate false positive samples based on competition
ssays. These competition assays are a tool to identify possible sig-
al contribution from unspeciﬁc antibody binding and additionally
nalyze all samples using a study-drug inhibited assay. This assay is
∗ Corresponding author. Tel.: +44 01524 59 23 18.
E-mail address: jaki.thomas@gmail.com (T. Jaki).
ttp://dx.doi.org/10.1016/j.jpba.2016.05.031
731-7085/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).basically set up identically to the uninhibited assay with the excep-
tion that all samples are pre-incubated with excess amount of free
speciﬁc protein antigen (“antigen competition”). Speciﬁc antibod-
ies directed against the particular antigen are bound in the form of
immune complexes in the liquid phase and subsequently removed
during washing steps. Hence, the speciﬁcity of antibodies detected
with the uninhibited assay can be conﬁrmed by a reduction of sig-
nal in the inhibited assay. Recently various methods for ﬁnding cut
points for screening assays [7,8] and conﬁrmatory assays [9] have
been evaluated.
One of the unexpected and striking ﬁndings when evaluating
the performance of conﬁrmatory assays [9] was that extremely
large differences between uninhibited and inhibited samples
are necessary to separate positive from negative samples. This
surprising ﬁnding led us to investigate the capability of the
multi-tier approach to separate positive and negative samples.
In this manuscript we will evaluate the ability of the multi-tier
approach for classifying samples in both simulations and real data
evaluations.2. Classifying samples
Previously a large number of different approaches for classify-
ing screening (e.g. [6,7]) and conﬁrmatory assays (e.g. [9]) have
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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een described. In this evaluation we consider 7 methods to be
sed in screening assays and three approaches for conﬁrmatory
ssays yielding 21 different combination of approaches. We  have
ttempted to be as comprehensive as possible in the methods
nvestigated, yet the sheer number of approaches currently in the
iterature disallowed a full evaluation. The most notable ideas that
ave not been considered here is the simpliﬁed decision tree in
10] and the ﬁxed percent inhibition method [6,9]. The former was
xcluded as initial evaluations revealed an undistinguishable per-
ormance to the decision tree in [6] while the latters subjective
hoice of what percentage ought to be used was prohibitive.
In this section we will describe the different methods for classi-
ying samples. The principle idea of each approach for conﬁrmatory
ssays is to determine if the change in assay signal with and
ithout pre-incubation of a sample with high amounts of the
herapeutic drug is large enough to be a relevant indicator to dis-
inguish between true positive and false positive samples. We  will
herefore consider the situation where measurements without pre-
ncubation for each sample are available (the screening data) and
hat measurements with and without preincubation are available
or conﬁrmation. For the latter we also assume pre-incubation is
uccessful and truly leads to inhibition. Moreover, we  assume that
ultiple runs (analyses) per sample are undertaken and that mea-
urements are corrected for run noise. As in [9] we will use an
verage of the runs per sample (e.g. mean per subject across runs) to
tilize multiple runs recognizing that more involved methods may
e necessary depending on the underlying experimental design
e.g. [11]). Measurements with pre-incubation of the therapeutic
rug will be referred to as “inhibited measurements” and without
ncubation as “uninhibited measurements”.
.1. Methods for classiﬁcation: Screening assays
.1.1. Method S1: 95th percentile
The cut point is found as the 95th percentile of the uninhibited
bservations.
.1.2. Method S2: Parametric method
The cut-off value is calculated as X¯ + z0.95 * SD, where X¯ and SD
re the mean and standard deviation of the uninhibited measure-
ents respectively and z0.95 is the 95% percentile of the standard
ormal distribution (approximately 1.645).
.1.3. Method S3: Robust parametric method
The cut point is found as X˜ + z0.95 * 1.483 * MAD, where X˜ and
AD are the median and median absolute deviation of the unin-
ibited measurements respectively and z0.95 is the 95% percentile
f the standard normal distribution as before.
.1.4. Method S4: Decision tree
The following decision tree, as described in [6], is used to ﬁnd
he cut-point.
. Perform a Shapiro–Wilks test [12] to assess normality of the
uninhibited data. If the p-value is <0.05 the data are log-
transformated.
. Calculate the 25% and 75% percentile, X0.25 and X0.75, of the
(transformed) data. Eliminate all data points outside the interval
[X0.25 − 1.5 * (X0.75 − X0.25); X0.75 + 1.5 * (X0.75 − X0.25)]. This cor-
responds to eliminating data that are classed as outliers in a
box–whisker plot (e.g. [13]).. Perform the Shapiro–Wilks test [12] to assess normality using
the remaining data. If the p-value is <0.05, use the 95% percentile
to calculate the intermediate cut point, otherwise the parametric
method is used.omedical Analysis 128 (2016) 166–173 167
4. If data were log-transformed take the anti-logarithm of the inter-
mediate cut point as ﬁnal cut point otherwise the intermediate
cut point is the ﬁnal cut point.
Note, that in general it is not recommended to test every data set
for normality and use the result to decide between parametric and
nonparametric statistical tests (e.g. [14,15]). This procedure has,
however, been proposed as a compromise between statistical rigor
and practicality.
2.1.5. Method S5: Mixture model
This method, which has been proposed in [7], aims to identify
if samples are negative or positive and then only uses the nega-
tive samples to ﬁnd the cut point. The approach uses (regression)
mixture models (e.g. [16–18]) that allow different populations (in
this application positive and negative subjects) to follow different
probability distributions.
The approach is to ﬁrstly identify, using the Bayesian Informa-
tion Criterion (BIC) if there is more than one population in the
screening data. If there is more than one population, then only
samples belonging to the larger population, which is assumed to
be corresponding to negative samples, will be used for cut point
determination while all screening data are used otherwise. The cut
point is then found as the 95th percentile of the observations. A
formal description and details on the speciﬁc implementation of
this method are provided in the Supplementary Material.
2.1.6. Method S6: Prediction intervals
This approach is advocated in [8] and is based on obtaining inter-
vals for future observations based on m historical observations. In
particular the cut-point is found as X¯ + t0.95,m−1 * SD *
√
1 + 1/m,
where X¯ and SD are the mean and standard deviation of the
uninhibited measurements respectively and t0.95,m−1 is the 95%
percentile of a t-distribution with m − 1 degrees of freedom.
2.1.7. Method S7: Experimental approach
The experimental approach, which utilizes screening and con-
ﬁrmatory assay data together obtains the cut point through the
following steps:
1. Find a preliminary cut point for the inhibited samples based on
the 95% percentile method;
2. Use the preliminary cut point to classify uninhibited values into
positive and negative samples;
3. Create a new dataset containing all screening samples below the
preliminary cut point and all screening samples larger than the
preliminary cut-off value provided that the conﬁrmatory value
is larger than the screening value. The second set of samples
is included as such observations correspond to an nonspeciﬁc
signal (false positives);
4. Use the 95% percentile method with the new dataset to get the
ﬁnal cut-point.
2.2. Methods for classiﬁcation: Conﬁrmatory assays
2.2.1. Method C1: Parametric difference
Find the difference between uninhibited and inhibited measure-
ment for each sampleThe cut point is found as cD = D¯ + z0.999 ∗ D where D¯ is the aver-
age difference across all samples, D is the corresponding standard
deviation and z0.999 is the 99.9% percentile of the standard normal
distribution (approximately 3.09).
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.2.2. Method C2: Parametric % inhibition
For each sample ﬁnd the percent change in inhibition as
 = 100 ∗
(
1 − inhibited measurement
uninhibited measurement
)
he inhibition based cut point is found as cI = I¯ +  z0.999 ∗ I where
is the average percent change in inhibition across all samples,
I is the corresponding standard deviation and z0.999 is the 99.9%
ercentile of the standard normal distribution as before.
.2.3. Method C3: t-test
Perform a one-sided 2-sample t-test of all runs of the
og-transformed study drug inhibited values against the log-
ransformed uninhibited values for each sample. If the resulting
-value is less than 0.01 the sample is classed positive.
. Simulation of multi-tiered approach
We  begin by considering simulations of the 2-stage classiﬁca-
ion approach in this section. This has the advantage that it is exactly
nown whether a speciﬁc value is positive or negative, allowing for
n informed comparison of the different approaches. For a more
n-depth evaluation we will consider samples to be either truly
ositive, false positive or truly negative. For simulation, true posi-
ive samples show high measurements when uninhibited, but low
alues under inhibition, false positives have high measurements
hen uninhibited and inhibited while true negative samples have
ow measurements under both conditions.
We will generate data for this evaluation in two parts. In the
rst part, data that are used to determine the cut-points are simu-
ated from a population that only contains negative samples. Both
nhibited and uninhibited samples will be generated and we  will
se 160 samples in the ﬁrst part of the evaluation as previous work
7,9] suggests limited impact of sample size. The second part of
he data are used to evaluate the performance of the classiﬁcation
ethods and cut-points found based on the ﬁrst set of data. The
ata are generated to contain 85% true negative samples, 10% of
he data are truly positive and 5% are false positive samples. To
nsure accurate estimation of the classiﬁcation rates we will sim-
late 1000 samples and estimate the classiﬁcation rates based on
hese data. Both normal and log-normally distributed data are eval-
ated and 1000 simulation runs are performed. Three runs will
e used for establishing cut points and evaluating classiﬁcation.
able 1 (Supplementary Material) shows the exact parameters used
o generate the data. Note that, while only a limited set of evalu-
tions are presented here, many more simulations have been run.
s the conclusions from these were qualitatively the same as the
nce presented, we have omitted them here for brevity.
To evaluate the performance of the classiﬁcations we will look
t the proportion of correctly classiﬁed true positive, true nega-
ive and false positive samples averaged over 1000 simulation runs.
e begin, however, by considering the number of samples that are
elected for conﬁrmation as this number has direct implications for
he practicability of the classiﬁcation method. Note, that we  expect
round 200 observations to be classed as positive at this stage, as
0% of the 1000 observations are truly positive, 5% are false positive
nd the cut-points are found so that 5% error in classing negative
amples are allowed. Fig. 1 shows the distribution of the num-
er of samples that are classed as positive based on the screening
ata for the seven different methods. The ﬁrst notable observation
s that the experimental approach classes almost twice as many
bservations as positive than the other approaches. Consequently
he risk of missing a positive signal at this stage is lower for that
pproach while at the same time the risk of including large numbers
f truly negative samples in the conﬁrmation step is also increased.omedical Analysis 128 (2016) 166–173
Secondly, the difference in number of samples classed positive is
(on average) quite similar for all the other approaches although
more variability is observed in the mixture approach. It is how-
ever notable that for the situation with a small difference between
positive and negative samples, only about 100 samples are consid-
ered positive and hence a high risk of false negatives exists, while
the larger differences between positive and negative samples yield
numbers quite close to the expected 200 samples. Additional eval-
uations (not shown) suggest, that the number of positive samples is
very stable once the difference between positive and negative sam-
ples is sufﬁciently large. For normally distributed data, for example,
this difference needs to be around 2.5 standard deviations.
Next we evaluate the ability of the various approaches to clas-
sify correctly. The objective of this evaluation is twofold. Firstly we
wish to see how well commonly used classiﬁcation approaches for
immunogenicity assays work in realistic situations and secondly
determine which approach (that is which combination of meth-
ods for cutpoint calculation for screening assay and conﬁrmation
assay) is best. We  begin by focusing on the overall classiﬁcation
rates, when the robust parametric approach, which in [7] is found
to be one of the best performing methods, is used for the screening
assays. Fig. 2 shows a clear separation between the methods for
classiﬁcation for conﬁrmatory assays investigated. The % inhibi-
tion methods performs far worse than the other two  approaches
in classifying true positive samples, when the robust parametric
method is used for the screening assays. The difference between
the parametric difference and the t-test is more nuanced, how-
ever. The t-test performs best classifying true positive samples –
only for large difference between positive and negative samples
the parametric difference is marginally better. When looking at the
classiﬁcation performance of the different approaches of samples
that are truly negative, the parametric difference is slightly bet-
ter, although the t-test also results in a large proportion of correct
classiﬁcations. This small difference is expected, however, as the
number of correct classiﬁcations is dominated by the method used
for the screening data. The parametric difference is clearly superior
to the t-test in classifying false positives which only achieves about
80% correct classiﬁcations. It also shows a peculiar dip in the pro-
portion of correct classiﬁcations for medium differences between
positive and negative samples.
The evaluation shown in Fig. 2 focuses on the situation, where
the robust parametric difference is used for the screening assays.
Although the classiﬁcation rates do differ slightly, when using
other methods during the screening phase, the relative patterns
described above are the same. It is notable, that the difference
between positive and negative samples needs to be quite large
in order to see good classiﬁcation of true positive samples, while
the classiﬁcation of true negatives and false positives is much
less effected by that difference. To investigate the combination of
methods further, we now look at the different methods for classi-
fying screening assay data. Fig. 3 shows the overall classiﬁcation
rates for each screening classiﬁcation method when the conﬁr-
mation uses the t-test. The parametric and the robust parametric
method result in the best classiﬁcation rates for truly positive
samples while all methods appear to give good classiﬁcation of
negative samples. The mixture model approach and the predic-
tion interval are best in determining false positive samples. Overall,
the percentile approach and the parametric methods appear to
provide best results. As the difference between methods is most
pronounced for small differences between the positive and neg-
ative samples, the graph displays a 1 and 1.2 standard deviation
difference for normal and log-normal data, respectively. The over-
all patterns are the same as this difference increases, however. It
is worth noting that the methods become almost indistinguish-
able for differences that classify an adequate proportion of subjects
correctly.
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Fig. 1. Boxplots of the number of samples exceeding the screening cut-point for the different methods. Panels (a) and (b) display normally distributed data with 1 and 5
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The evaluations so far clearly indicate that the method used for
creening has little bearing on the overall ability to classify cor-
ectly when using a 2-tier approach while the method used for
onﬁrmation is of high importance. A simple t-test performs best
n classifying true positive samples but does not do so well in clas-
ifying false positives. In contrast a simple difference approach has
ood classiﬁcation for false positives, yet only results in adequate
lassiﬁcation rates if the difference between positive and negative
amples are very large. This raises the immediate question whether
 conﬁrmatory assay should be used at all. To investigate this fur-
her we contrast the classiﬁcation rates after screening only and
fter screening and conﬁrmation. The robust parametric method
s used for the screening assays while the parametric difference is
sed for conﬁrmation.
Fig. 4 shows that using a conﬁrmatory assay has an notable effect
n the ability to classify positive sample correctly for small to mod-
rate differences between positive and negative samples. At the
ame time the conﬁrmatory assays do result in a much improved
alse positive rate. When using the % inhibition approach the results
re even worse in terms of classifying positive samples. The results
or the t-test are closer to the ones obtained by using screening
lone but result in much worse classiﬁcation for false positive sam-
les (see Fig. 2). (c) and (d) display log-normally distributed data with 1.2 and 4 standard deviations
4. Differences in methods for a speciﬁc example
The previous evaluations were based on simulated data but sug-
gest that it may  not be beneﬁcial for classifying ADA positive and
ADA negative samples to use a conﬁrmation assay. In this section
we consider a real dataset (illustrated in Fig. 5 and full dataset pro-
vided in Table 2 (Supplementary Material)) to highlight where the
different approaches lead to distinct conclusions.
The data set was  generated by means of a direct-binding
enzyme-linked immunosorbent assay (ELISA). The ELISA was
designed to detect total Ig antibodies (i.e. isotypes IgG, IgM and IgA)
speciﬁcally directed against a particular protein antigen. Plasma
samples from 160 clinically healthy plasma donors were analyzed,
each using three runs with and without inhibition. For the unin-
hibited runs, micro-titer plates (Nunc/ThermoScientiﬁc, Denmark)
were coated with the particular protein antigen. Human  plasma
samples from healthy plasma donors (Baxter AG, Austria) were
incubated on the plate at a dilution of 1:20. Antibodies directed
against the antigen that were present in the samples bound to the
antigen. After several washing steps, the antigen–antibody com-
plexes was  detected using a horseradish peroxidase (HRP)-coupled
secondary antibody (goat anti-human Ig antibody; AbD Serotec,
Germany). The amount of bound secondary antibody was  measured
170 T. Jaki et al. / Journal of Pharmaceutical and Biomedical Analysis 128 (2016) 166–173
Fig. 2. Classiﬁcation rates across the two stages when the robust parametrics method is used for the screening assays and different approaches are utilized for the conﬁrmation.
A  range of differences between positive and negative samples is investigated.
Fig. 3. Classiﬁcation rates across the two stages when the t-test is used for the conﬁrmatory assays and different approaches are utilized for the screening assays. A difference
of  1 and 1.2 standard deviations between positive and negative samples for normal and log-normal data, respectively are used.
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aig. 4. Classiﬁcation rates when the robust parametric method is used for screenin
etween positive and negative samples is investigated.
y an HRP enzyme-dependent color-change reaction using TMB
3,3′,5,5′-tetramethylbenzidine solution, AbD Serotec, Germany) as
ubstrate. The color reaction is directly proportional to the amount
f bound antibodies. The micro-titer plates were subsequently
ead with a plate photometer (ELISA reader Synergy HT; Bio-Tek,
SA) in a dual mode at 450 nm measuring wavelength and 630nm
eference wavelength. The dual mode allows the elimination of
easurement errors due to scratches or dirt on the micro-titer
lates. Delta-OD (=optical density at 450 nm minus optical den-
ity at 630 nm)  corrected by the blank value is taken into account
s optical density (OD) for evaluation. Each sample was  analyzed
n independent triplicates by two different analysts on different
ays.
As a tool to identify possible signal contribution from unspeciﬁc
ntibody binding, all samples were additionally analyzed using a
tudy-drug inhibited assay (i.e. conﬁrmatory assay). This assay is
asically set up identically to the uninhibited assay with the excep-
ion that all samples are pre-incubated with excess amount of free
peciﬁc protein antigen (“antigen competition”). Speciﬁc antibod-
es directed against the particular antigen are bound in the form of
mmune complexes in the liquid phase and subsequently removed
uring washing steps. Hence, the speciﬁcity of antibodies detected
ith the uninhibited assay can be conﬁrmed by a reduction of OD
ignal in the inhibited assay.
Close examination of the data shows that a large variability both
etween subjects and between runs exists in this dataset. Similarly
ne can observe that the responses increase after the addition of the
ntigen for a number of subjects. This is somewhat surprising as it isFig. 5. Histogram of the average screening and competition values per subject.not consistent with the inhibition model and suggests some other
confounding factor. In such a situation a more advanced modeling
approach that accounts for this confounding factor may  be called
for. For the purpose of illustration, however, we will keep with the
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immunogenicity screening assay cut points, J. Immunol. Methods 373 (1–2)ig. 6. Histogram of number of samples classiﬁed as positive after screening (big
oxes) and after conﬁrmation for the different methods.
asic approaches and illustrate the difference in ﬁnal classiﬁcation
esulting from different combinations of methods.
Fig. 6 shows the number of samples that are classed as positive
or the different stages and methods. It can be seen that the differ-
nt methods for screening classify between 8 and 19 observations
s positive. Looking at the methods for conﬁrmation within each of
he screening results it is ﬁrstly notable that the inhibition based
ethod classes the most samples as positive while the difference
ased method does not class any as positive. More interestingly,
owever, is the fact that, despite substantially different numbers of
amples being classed positive during screening, the conﬁrmation
tep does yield very consistent results. The t-test and the difference
ased method class exactly one and none sample, respectively, as
ositive, irrespective of the screening method used. This under-
ines once more how large the impact of the conﬁrmation step is in
omparison to the screening step.
. Discussion
In this paper we have evaluated the ability of the multi-tier
pproach to classify positive and negative samples. We  ﬁnd
hat, irrespective of the speciﬁc methods used for determining
utpoints for screening and competition assay the approach is able
o correctly identify truly negative samples as such. Similarly there
s high conﬁdence in the correct classiﬁcation of false positive
amples. Unfortunately, however, we also ﬁnd that in general
he two-tier approach only identiﬁes positive samples correctly
f very large differences between positive and negative samples
re present. For small differences between positive and negative
amples positive samples are frequently misclassiﬁed. We  also ﬁnd
hat this performance at small differences between inhibited and
ninhibited samples is due to a lack of sensitivity of the methods
f classiﬁcation for the competition based conﬁrmatory assay used
n this study. As a consequence, samples with a low signal in the
creening assay should not be applied to the competition based
onﬁrmatory assay because of the low conﬁdence of a correct true
ositive evaluation. Instead, a lower limit for conﬁrmed positiveomedical Analysis 128 (2016) 166–173
samples should be introduced in addition to the lower limit of
detection of any antibody in the screening assay [19]. For moderate
and small differences using the competition based conﬁrmatory
approach decreases the number of correctly classiﬁed positive
samples drastically.
In our evaluation we  have focused on simple methods for clas-
siﬁcation (a summary of the performance for all combinations of
methods is given in Table 3 (Supplementary Material)) and have
not considered more complex methods such as [11]. We have done
so as the simulated conditions we have considered meant that these
simple approaches were appropriate. It is clear, however, that more
complex real life settings and experimental designs will require
more complex methods for analysis. Similarly we  have focused on
scenarios that did not provide any particular additional challenges
such as positive samples when establishing the screening cut point.
It is clear that the ﬁndings still have general applicability even if
more challenging scenarios are considered.
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